AAAAAA
Results:
1-9
|
Results: 9
Authors:
Dowsett, M
Bundred, NJ
Decensi, A
Sainsbury, RC
Lu, YL
Hills, MJ
Cohen, FJ
Veronesi, P
O'Brien, MER
Scott, T
Muchmore, DB
Citation: M. Dowsett et al., Effect of raloxifene on breast cancer cell Ki67 and apoptosis: A double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients, CANC EPID B, 10(9), 2001, pp. 961-966
Authors:
Cohen, FJ
Lu, YL
Citation: Fj. Cohen et Yl. Lu, Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials, MATURITAS, 34(1), 2000, pp. 65-73
Authors:
Cohen, FJ
Watts, S
Shah, A
Akers, R
Plouffe, L
Citation: Fj. Cohen et al., Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60, OBSTET GYN, 95(1), 2000, pp. 104-110
Authors:
Gradishar, W
Glusman, J
Lu, Y
Vogel, C
Cohen, FJ
Sledge, GW
Citation: W. Gradishar et al., Effects of high dose raloxifene in selected patients with advanced breast carcinoma, CANCER, 88(9), 2000, pp. 2047-2053
Authors:
Johnston, CC
Bjarnason, NH
Cohen, FJ
Shah, A
Lindsay, R
Mitlak, BH
Huster, W
Draper, MW
Harper, KD
Heath, H
Gennari, C
Christiansen, C
Arnaud, CD
Delmas, PD
Citation: Cc. Johnston et al., Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women - Three-year data from 2double-blind, randomized, placebo-controlled trials, ARCH IN MED, 160(22), 2000, pp. 3444-3450
Authors:
Davies, GC
Huster, WJ
Shen, W
Mitlak, B
Plouffe, L
Shah, A
Cohen, FJ
Citation: Gc. Davies et al., Endometrial response to raloxifene compared with placebo, cyclical hormonereplacement therapy, and unopposed estrogen in postmenopausal women, MENOPAUSE, 6(3), 1999, pp. 188-195
Authors:
Ettinger, B
Black, DM
Mitlak, BH
Knickerbocker, RK
Nickelsen, T
Genant, HK
Christiansen, C
Delmas, PD
Zanchetta, JR
Stakkestad, J
Gluer, CC
Krueger, K
Cohen, FJ
Eckert, S
Ensrud, KE
Avioli, LV
Lips, P
Cummings, SR
Citation: B. Ettinger et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial, J AM MED A, 282(7), 1999, pp. 637-645
Authors:
Lee, CY
Cohen, FJ
Wu, HB
Ooi, GT
Rechler, MM
Citation: Cy. Lee et al., The absence of 150-kDa insulin-like growth factor complexes in fetal rat serum is not due to a lack of functional acid-labile subunit, HORMONE MET, 31(2-3), 1999, pp. 182-185
Authors:
Mitlak, BH
Cohen, FJ
Citation: Bh. Mitlak et Fj. Cohen, Selective estrogen receptor modulators - A look ahead, DRUGS, 57(5), 1999, pp. 653-663
Risultati:
1-9
|